文献速递认知障碍与痴呆

淀粉样蛋白正电子发射断层扫描与未选择记忆门诊队列中诊断及患者治疗变化的相关性:ABIDE项目

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项前瞻性诊断研究在未选择的记忆门诊队列中评估淀粉样蛋白PET与诊断、诊断信心及治疗变化的相关性。507例患者中,淀粉样蛋白PET阳性242例(48%),疑似病因在125例(25%)中发生变化,诊断信心从80%升至89%,123例(24%)治疗后发生改变。

要点

  • 淀粉样蛋白PET阳性242例(48%),阴性结果较阳性结果更常引起疑似病因改变(31% vs 18%)。
  • 疑似病因改变在年龄>65岁患者中更常见(29% vs 20%)。
  • 平均诊断信心从80%升至89%,123例(24%)治疗后发生改变。

核心结论

  • 这项前瞻性诊断研究为在研究环境中验证淀粉样蛋白PET与在日常临床实践中实施该诊断工具之间搭建了桥梁。
  • 淀粉样蛋白阳性和阴性结果均与诊断和治疗变化有显著关联,无论患者有无痴呆。

研究设计与样本

  • 前瞻性诊断研究,在VU大学医学中心三级记忆门诊于2015年1月至2016年12月期间,将使用氟-18氟比他班进行的淀粉样蛋白PET作为常规痴呆诊断检查的一部分提供给866例患者。
  • 866例中476例(55%)纳入,32例(4%)排除,358例(41%)未参与;另从乌得勒支大学医学中心记忆门诊纳入31例轻度认知障碍患者以富集样本。
  • 最终分析507例患者(平均[SD]年龄65(8)岁;201例女性[39%];平均[SD]简易精神状态检查评分25(4))。
  • 神经科医生为每例患者确定淀粉样蛋白PET前和后的诊断(包括临床综合征和疑似病因,置信度0%至100%)以及治疗(辅助检查、药物和护理),每例患者在扫描后1年接受临床随访。

主要发现

  • 507例患者中,164例(32%)为阿尔茨海默病痴呆,70例(14%)为非阿尔茨海默病痴呆,114例(23%)为轻度认知障碍,159例(31%)为主观认知下降。
  • 淀粉样蛋白PET结果阳性242例(48%)。
  • 疑似病因在125例(25%)中于淀粉样蛋白PET后发生变化,阴性结果后改变82/265例(31%),阳性结果后改变43/242例(18%)(P < .01)。
  • 疑似病因的PET后改变在年龄>65岁患者中比年龄<65岁患者更常见(74/257例[29%] vs 51/250例[20%];P < .05)。
  • 平均诊断信心(SD)从80(13)%升至89(13)%(P < .001);123例(24%)患者在PET后治疗发生改变,主要与额外检查和治疗相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous studies have evaluated the diagnostic effect of amyloid positron emission tomography (PET) in selected research cohorts. However, these research populations do not reflect daily practice, thus hampering clinical implementation of amyloid imaging. OBJECTIVE: To evaluate the association of amyloid PET with changes in diagnosis, diagnostic confidence, treatment, and patients' experiences in an unselected memory clinic cohort. DESIGN, SETTING, AND PARTICIPANTS: Amyloid PET using fluoride-18 florbetaben was offered to 866 patients who visited the tertiary memory clinic at the VU University Medical Center between January 2015 and December 2016 as part of their routine diagnostic dementia workup. Of these patients, 476 (55%) were included, 32 (4%) were excluded, and 358 (41%) did not participate. To enrich this sample, 31 patients with mild cognitive impairment from the University Medical Center Utrecht memory clinic were included. For each patient, neurologists determined a preamyloid and postamyloid PET diagnosis that existed of both a clinical syndrome (dementia, mild cognitive impairment, or subjective cognitive decline) and a suspected etiology (Alzheimer disease [AD] or non-AD), with a confidence level ranging from 0% to 100%. In addition, the neurologist determined patient treatment in terms of ancillary investigations, medication, and care. Each patient received a clinical follow-up 1 year after being scanned. MAIN OUTCOMES AND MEASURES: Primary outcome measures were post-PET changes in diagnosis, diagnostic confidence, and patient treatment. RESULTS: Of the 507 patients (mean [SD] age, 65 (8) years; 201 women [39%]; mean [SD] Mini-Mental State Examination score, 25 [4]), 164 (32%) had AD dementia, 70 (14%) non-AD dementia, 114 (23%) mild cognitive impairment, and 159 (31%) subjective cognitive decline. Amyloid PET results were positive for 242 patients (48%). The suspected etiology changed for 125 patients (25%) after undergoing amyloid PET, more often due to a negative (82 of 265 [31%]) than a positive (43 of 242 [18%]) PET result (P < .01). Post-PET changes in suspected etiology occurred more frequently in patients older (>65 years) than younger (<65 years) than the typical age at onset of 65 years (74 of 257 [29%] vs 51 of 250 [20%]; P < .05). Mean diagnostic confidence (SD) increased from 80 (13) to 89 (13%) (P < .001). In 123 patients (24%), there was a change in patient treatment post-PET, mostly related to additional investigations and therapy. CONCLUSIONS AND RELEVANCE: This prospective diagnostic study provides a bridge between validating amyloid PET in a research setting and implementing this diagnostic tool in daily clinical practice. Both amyloid-positive and amyloid-negative results had substantial associations with changes in diagnosis and treatment, both in patients with and without dementia.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. de Wilde A, van der Flier WM, Pelkmans W, et al. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurol. 2018. PMID: 29889941. doi:10.1001/jamaneurol.2018.1346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。